On February 26, Sunnyou Medical, a STAR Market-listed company, disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary, along with the successful creation of a nearly 100-person strong robotics research and development center. This news quickly drew market attention, marking Sunnyou Medical's formal entry into the medical robotics field, building on its renown in rehabilitation medical devices.

According to the disclosed information, Sunnyou's robotics R&D team, based in Shanghai, Zhengzhou, and Anyang headquarters, has gathered technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. Their expertise covers core areas including mechanical design, algorithm development, hardware integration, and software systems. More notably, the team has accumulated years of experience in developing rehabilitation equipment and robots, providing a solid foundation for their technological breakthroughs.

The dual drivers of policy and capital were also important factors for Sunnyou's entry into the market. In 2023, the Ministry of Industry and Information Technology and sixteen other departments jointly issued the "Robotics +" Application Action Implementation Plan, explicitly listing healthcare as a key area for robotics applications. Beijing, Shanghai, and other regions have introduced special subsidy policies, with the highest reward for a single medical robotics project reaching up to 10 million yuan. In the capital markets, the financing momentum in the medical robotics sector has continued to rise, with over 30 related financing events in China in 2023, and the largest single amount reaching 1.5 billion yuan. Sunnyou's entry into this sector at this time allows it to fully benefit from policy incentives while creating favorable conditions for future spin-off financing.

Notably, Sunnyou Medical's 2023 financial report shows that its net profit attributable to shareholders dropped by 49.72% year-on-year. A closer look at the financial details reveals that the decline in net profit was primarily due to two main pressures:

• Industry Cyclical Adjustment: In 2023, public hospitals in China faced increased financial pressure, leading to delays in some rehabilitation equipment procurement projects.
  
• Surge in R&D Investment: The company's R&D expenses increased by 37% year-on-year, with a significant rise in the proportion allocated to new directions such as robotics and AI.
  

Despite short-term pressure, the logic of strategic transformation is clearly visible:

• R&D Investment Converted into Technology Reserve: By the end of 2023, Sunnyou Medical added 152 patents, 15% of which involve robot-related technologies.
  
• Order Structure Optimization: The robotics subsidiary has signed pilot agreements with multiple Class III hospitals, with the average order value increasing 3-5 times compared to traditional equipment.
  
• Policy Subsidies Offset Costs: In 2023, the company received government subsidies of 120 million yuan, a 68% increase year-over-year, partially covering R&D expenses.
  

It can be seen that the decline in net profit is more of a phased performance during the strategic investment period. As robotic products enter the commercialization stage, their high gross margin characteristics (medical robot gross margins generally exceed 60%) are expected to become a new source of profit growth.

Sunnyou Medical is not an isolated case. Driven by the acceleration of aging and the policy promoting domestic substitution of surgical robots, China's medical device giants have sparked a wave of enthusiasm for the layout of medical robots:

• Minimally Invasive Medical: Its Minimally Invasive Robotics listed on the Hong Kong Stock Exchange, with the Tuomi laparoscopic surgical robot completing over 10,000 clinical cases;
  
• Weigao Group: Collaborated with Tianjin University to develop orthopedic surgical robots, approved as a national innovative medical device;
  
• United Imaging Healthcare: Launches uRT-ART Radiation Therapy Robot, Achieving Sub-Millimeter Precision Localization;
  
• TINAVI: Focused on orthopedic navigation robots, with a market share exceeding 75%.
  

Compared with these enterprises, Sunnyou has chosen a differentiated path — focusing on rehabilitation scenarios and avoiding the "red ocean competition" of surgical robots. Relying on its existing rehabilitation equipment channels, Sunnyou has been able to quickly expand its market. At the same time, it combines AI diagnostic data with robot training in a closed loop to build a rehabilitation effectiveness evaluation system. Through the "equipment + service" model, Sunnyou creates an ecosystem for home rehabilitation robots after hospital discharge, paving a distinctive path of differentiated development.